Optimizing IL-6 Detection for High-Throughput Screening
This webinar is Part 5 of the Lumit® Technology Webinar Series.
In this webinar, you will learn about:
- New technologies for high-throughput assays to study GPCR, protein degradation, and targeted cell killing
- Using NanoBRET® technology for protein:protein interaction, target engagement and target deconvolution applications
- Setting up a high throughput screen for detection of cytokine
Summary
Lumit® Technology Webinar Series
Immunoassays are an essential tool for life science researchers, widely used for decades. Applying bioluminescent technology to this well-accepted assay format to create Lumit® Immunoassays has made analyte detection faster and easier than ever before. This webinar series will introduce you to Lumit® Immunoassay technology and highlight key research areas where bioluminescent immunoassays have supported research discoveries.
Part 5: Optimizing IL-6 for High-Throughput Screening
In the fifth part of this series, we will share best practices for high-throughput amenable immunoassays. Dr. Conkright-Fincham, Promega, will discuss considerations for scaling assays from a single 96-well plate to many 384-well plates. Nick Verstraeten from Galapagos, a biotechnology company, will highlight optimization tips from their IL-6 screening campaign using Lumit® detection technology.
Other Webinars in this Series:
Bioluminescent Analyte Detection with Lumit® Immunoassays
Using Lumit® Technology to Address Inflammasome-mediated Cytokine Release
Ask the Experts Forum: Implementing Lumit® Immunoassays
Advances in Glucagon Detection Supporting Diabetes and Metabolic Disorder Research
Speakers
Julie Conkright-Fincham, PhD
Strategic Collaborations Manager
Promega
Julie is a Strategic Collaborations Manager at Promega, supporting the sales team to understand their customer's assay needs and suggesting products to fulfill those needs. She works with customers, R&D scientists, and Promega's custom assay teams to design new assays using Promega’s technology components. Lastly, she communicates customer’s unmet needs and challenges to R&D and Promega leadership to advocate for new product development. Julie focuses on Promega’s TPD, TE, PPI, Lumit, cell health and metabolism portfolios.
Julie conducted her graduate research at Cincinnati’s Children’s Hospital Medical Center and received her Ph.D. in Molecular and Developmental Biology from the University of Cincinnati College of Medicine. After her postdoctoral fellowship at The Scripps Research Institute, she was the Director of the Cell-based Screening Facility at Scripps, FL, and then, the Head of Screening at the Stowers Institute, where she provided high-throughput assay development, screening, and automation support for researchers.
Nick Verstraeten
Senior Lab Technician
Galápagos